Study ID: IXR-207-21-189 / NABTT 0304

Study Title

Safety and Efficacy of Talampanel in Glioblastoma Multiforme

Teva Identifier

IXR-207-21-189 / NABTT 0304

ClinicalTrials.gov Identifier

NCT00267592

Study Status

Completed

Trial Condition(s)

Glioblastoma Multiforme

Interventions

Drug: Talampanel | Radiation: Radiation Therapy (RT) 5 days a week + | Drug: temozolomide(TMZ) 75mg | Drug: adjuvant TMZ 200mg

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
ClinicalTrials.gov study records with inclusion and exclusion criteria
cancer icon for clinical trials

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years and older

Trial Duration

12/01/2005 - 02/01/2011

Phase

Phase 2

Study Type

Interventional